Overview

* GH Research ( GHRS ) Q2 net loss beats analyst expectations, per LSEG data

* Cash position improved due to $150 mln public offering in Q1 2025

* R&D expenses decreased, G&A expenses increased compared to last year

Result Drivers

* FDA ENGAGEMENT - Ongoing discussions with FDA regarding GH001 IND application clinical hold

* COSTS DROP - R&D costs decline on drop in clinical development activities and recognition R&D tax credit, offset by higher employee expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.15

Q2 Net Beat -$9.29 -$12.90

Income mln mln (7

Analysts

)

Q2 Miss -$14.70 -$14.30

Income mln mln (7

From Analysts

Operatio )

ns

Q2 Beat -$9.29 -$12.90

Pretax mln mln (7

Profit Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for GH Research PLC ( GHRS ) is $32.00, about 62% above its August 6 closing price of $12.15

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)